Aptus Endosystems, a Baird Venture Partners portfolio company, Completes Enrollment in STAPLE-2 Pivotal Study

 
February 10, 2009
 
Aptus Endosystems Inc., a medical device company developing advanced technology for the endovascular treatment of aortic aneurysms, today announced it has completed primary enrollment in the STAPLE-2 Pivotal Study of the Aptus Endovascular AAA Repair System. STAPLE-2 is the company’s US pivotal clinical study to demonstrate the safety and effectiveness of the Aptus Endovascular AAA Repair System.

Read the full release
 
 
Careers|Help|Site Map|Important Disclosures|Privacy Policy|Code of Conduct|Financial Information|Business Continuity
©2010 Robert W. Baird & Co. Incorporated.
The services featured on this Web site may not be available in all jurisdictions or to all persons/entities. For more information, please see Important Disclosures. Robert W. Baird & Co. Incorporated. Member SIPC.